Premenopausal adjuvant endocrine therapy options

What should be chosen for premenopausal adjuvant endocrine therapy? Women often experience early menopause due to work pressure and irregular lifestyle, which not only harms their own bodies, but also accelerates the aging of patients. Patients must understand their symptoms in daily life, so as to achieve early detection, early treatment and early recovery.

1. Tamoxifen for 5 years.

2. Treat with tamoxifen for 2-3 years. If you enter menopause, you can switch to aromatase inhibitors for a total of 5 years. If you enter menopause after 5 years of tamoxifen treatment, switch to letrozole for subsequent intensive treatment for 2-5 years.

3. Young patients with high-risk recurrence factors (such as poor tumor differentiation, lymph node metastasis, vascular tumor thrombus, etc.) can consider ovarian function suppression (laparoscopic bilateral ovarian surgery or use of Noradrena, subcutaneous injection, once every 28 days) and then choose tamoxifen (TAM) or aromatase inhibitors (including letrozole, anastrozole, exemestane) for treatment.

4. For some patients who are not suitable for tamoxifen treatment, aromatase inhibitor treatment can be considered after effective ovarian function suppression.